The Lipitor Files: A Maze Of Plot Twists Leads To A Cliffhanger Worthy Of A "Thriller"
This article was originally published in PharmAsia News
A look at the creation of the mammoth multi-billion dollar brand and its momentous journey though its life cycle.
You may also be interested in...
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
Lipitor Generics: Ranbaxy Still In The Driver's Seat As Court Dismisses Mylan Lawsuit Against U.S. FDA
Two unresolved factual matters stand in the way of Mylan Pharmaceuticals Inc.' s bid to sue U.S. FDA over generic marketing exclusivity for Pfizer's Lipitor, a U.S. federal judge ruled May 2
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage